H.C. Wainwright reiterates Buy rating on Viking Therapeutic stock

Investing.com - H.C. Wainwright has maintained its Buy rating and $102.00 price target on Viking Therapeutic (NASDAQ:VKTX) following the company’s third-quarter financial results. This aligns with the broader analyst consensus, as revealed by InvestingPro data, with analyst targets ranging from $33 to $125.

Viking reported earnings per share (EPS) of ($0.81) for the third quarter of 2025, missing both H.C. Wainwright’s estimate of ($0.71) and the consensus estimate of ($0.67).

The company ended the quarter with a strong financial position, reporting $715 million in cash on hand.

H.C. Wainwright noted that Viking continues to make significant progress on its VK2735 drug candidate, advancing both the subcutaneous and oral formulations.

The firm’s maintained price target of $102 represents substantial upside potential from Viking’s current trading levels.

In other recent news, Viking Therapeutics reported its third-quarter 2025 earnings, which revealed a larger-than-expected loss. The company posted an earnings per share (EPS) of -$0.81, falling short of the anticipated -$0.70. Despite this financial setback, Viking Therapeutics announced significant progress in its obesity drug portfolio. The company is ahead of schedule in enrolling participants for its Phase 3 VANQUISH studies, with the first study expected to complete enrollment in the fourth quarter of 2025 and the second in the first quarter of 2026. BTIG has reiterated its Buy rating on Viking Therapeutics, maintaining a price target of $125.00, citing the advancements in the obesity drug program. Analysts from BTIG expect potential data readouts from these studies in mid-to-second half of 2027. These developments highlight the company’s ongoing efforts in the obesity treatment sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.